TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01516645

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KHK2898
Description: injection
Study: NCT04282720

Intervention type: DEVICE
Group type: OTHER
Intervention: SurgiMend Mesh
Description: Following placement of SurgiMend mesh during laparoscopic hiatal hernia repair, patient will be scheduled for follow up using an upper GI series to check for recurrence of the hiatal hernia. Follow up upper GIs will be performed at 6 months post-surgery. Subjects will also complete a QOL survey to assess other GI associated symptoms before and after surgical repair. The QOL survey can be administered by phone by study team members
Study: NCT01714856

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropinirole hydrochloride CR 2mg Tablets
Description: Ropinirole is an orally administered non-ergoline dopamine agonist. Ropinirole is indicated for the treatment of the signs and symptoms of idiopathic Parkinson's disease.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropinirole hydrochloride CR 2mg Tablets
Description: Ropinirole is an orally administered non-ergoline dopamine agonist. Ropinirole is indicated for the treatment of the signs and symptoms of idiopathic Parkinson's disease.
Study: NCT03713996

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy for insomnia
Description: CBT-I is designed to change sleep habits as well as direct misconceptions about sleep and insomnia. Participants will receive several face-to-face interview techniques: sleep restriction therapy, stimulus control procedures, sleep hygiene, relaxation training and cognitive components. The intervention will be provided in 6-session (one session/week).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Health Education
Description: Participants in this arm will receive education in sleep hygiene, foot care, causes and diagnosis of diabetes, healthy diet, and physical activity. The education will be provided in 6-session (1 session/week).
Study: NCT01368887

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DPS-102
Description: The patient will apply the treatment twice daily in the morning and at bedtime on the involved area only. The scheduled treatment duration is 12 weeks. Patient to begin treatment on the night of Visit 1.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle / Placebo
Description: The patient will apply the vehicle twice daily in the morning and at bedtime on the involved area only. The scheduled treatment duration is 12 weeks. Patient to begin treatment on the night of Visit 1.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcipotriol Monotherapy
Description: The patient will apply the treatment twice daily in the morning and at bedtime on the involved area only. The scheduled treatment duration is 12 weeks. Patient to begin treatment on the night of Visit 1.
Study: NCT02382523

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acthar 80 unit injection
Description: Subjects not responding after 3 months of therapy (increasing creatinine; proteinuria not lower by 30%), will continue therapy at a dose 120 U SC x2/wk. Treatment will be discontinued if improvement is not observed 6 months after initiation of therapy.~If partial remission is achieved with Acthar 80 U SC x2/wk or x3/wk then Acthar will be increased to 120 U SCx2/wk; if remission is achieved, treatment will be continued at this dose for a total of 12 months; otherwise, if response is not observed after 3 months of treatment with the higher dose, we will resume therapy with the original dose/schedule. We will check anti-ACTH antibodies in non-responders.~If relapse occurs during the follow-up period, a 6 month treatment with Acthar at 120 U SC x2/wk will be started (not for partial responders), and the response will be assessed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acthar 80 unit injection
Description: Subjects not responding after 3 months of therapy (increasing creatinine; proteinuria not lower by 30%), will continue therapy at a dose 120 U SC x2/wk. Treatment will be discontinued if improvement is not observed 6 months after initiation of therapy.~If partial remission is achieved with Acthar 80 U SC x2/wk or x3/wk then Acthar will be increased to 120 U SCx2/wk; if remission is achieved, treatment will be continued at this dose for a total of 12 months; otherwise, if response is not observed after 3 months of treatment with the higher dose, we will resume therapy with the original dose/schedule. We will check anti-ACTH antibodies in non-responders.~If relapse occurs during the follow-up period, a 6 month treatment with Acthar at 120 U SC x2/wk will be started (not for partial responders), and the response will be assessed.
Study: NCT02920255

Intervention type: OTHER
Intervention: Diagnostic
Description: Measurement of spinal tilt

Intervention type: OTHER
Intervention: Diagnostic
Description: Measurement of spinal tilt

Intervention type: OTHER
Intervention: Diagnostic
Description: Measurement of spinal tilt
Study: NCT01507077

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZGN-440
Description: Subjects will receive ZGN-440 twice-weekly over a 4-week treatment period for a total of 8 doses. A range of doses will be evaluated.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ZGN-440 sterile diluent
Description: Subjects will receive placebo twice-weekly over a 4-week treatment period for a total of 8 doses. A range of doses will be evaluated.
Study: NCT03042299

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-536
Description: TAK-536 granules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-536
Description: TAK-536 granules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-536
Description: TAK-536 tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-536
Description: TAK-536 tablet.
Study: NCT00750451

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: low molecular weight heparin (enoxaparine sodium)
Description: 1 mg/kg/day subcutaneously in the luteal phase after IVF treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: crinone 8% gel
Description: routine luteal phase support with progesterone gel
Study: NCT03288077

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tryptophan
Description: Beverage including tryptophan
Study: NCT02885792

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Illness history
Description: Existing psychiatric and somatic diagnosis and treatment. Charlson co-morbidity Index.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Measure of social conditions
Description: A self-report questionnaire measuring social isolation, including relations to family and friends.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Measure of psychiatric condition
Description: This method measures symptom severity, therapeutic response and general improvement, suicidal ideation, cognitive insight and awareness of illness and need for treatment and the ability to relabel symptoms.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cardiovascular measurement
Description: This procedure is used to detect early identification of cardiovascular disease progression.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cardiovascular measurement
Description: This procedure is used to detect early identification of cardiovascular disease progression.
Study: NCT01398462

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CWP232291
Description: IV Infusion
Study: NCT04692090

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yoga
Description: Each class started with a check-in period during which any questions or concerns could be raised, after which the patients were given 5 minutes for seated meditation and 10 minutes for Shavasana (lying down in a restorative position).~The following poses were instructed during the course: standing poses with mountain pose (tadasana), chair pose (utkatasana), extended triangle pose (utthita trikonasana), extended side angle pose (utthita parshvakonasana), warrior 1 (virabhadrasana 1), warrior 2 (virabhadrasana 2) and tree pose (vrikshasana). The intervention was applied twice a week for 10 weeks.
Study: NCT02630706

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ertugliflozin 5 mg
Description: Ertugliflozin 5 mg oral tablet taken once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ertugliflozin 15 mg
Description: Ertugliflozin 15 mg (5-mg and 10-mg tablets) oral taken once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching ertugliflozin
Description: Placebo matching ertugliflozin (5-mg and/or 10-mg tablet) oral taken once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matching ertugliflozin
Description: Placebo matching ertugliflozin (5-mg and/or 10-mg tablet) oral taken once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Participants are to remain on their stable doses of metformin (oral, \>=1500 mg/day) while receiving blinded investigational product during the double-blind treatment period. Participants on metformin \<1500 at screening are up-titrated to \>= 1500 daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Participants are to remain on their stable doses of metformin (oral, \>=1500 mg/day) while receiving blinded investigational product during the double-blind treatment period. Participants on metformin \<1500 at screening are up-titrated to \>= 1500 daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin
Description: Participants are to remain on their stable doses of metformin (oral, \>=1500 mg/day) while receiving blinded investigational product during the double-blind treatment period. Participants on metformin \<1500 at screening are up-titrated to \>= 1500 daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glimepiride
Description: Glycemic rescue therapy with open-label glimepiride will be initiated in participants with glucose values exceeding protocol-specified values. Dosing and titration of open-label glimepiride rescue therapy will be at the Investigator's discretion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glimepiride
Description: Glycemic rescue therapy with open-label glimepiride will be initiated in participants with glucose values exceeding protocol-specified values. Dosing and titration of open-label glimepiride rescue therapy will be at the Investigator's discretion.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Glimepiride
Description: Glycemic rescue therapy with open-label glimepiride will be initiated in participants with glucose values exceeding protocol-specified values. Dosing and titration of open-label glimepiride rescue therapy will be at the Investigator's discretion.
Study: NCT04054414

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal Saline along with standard treatment
Description: The arm is for active comparison for PMZ-1620 (sovateltide), an endothelin-B receptor agonist. PMZ-1620 has the potential to be a first-in-class neuronal progenitor cell therapeutics that is likely to promote quicker recovery and improve neurological outcome in cerebral ischemic stroke patients. Normal saline (vehicle) with standard treatment will be provided.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PMZ-1620 along with standard treatment
Description: PMZ-1620 (sovateltide) is an endothelin-B receptor agonist. PMZ-1620 has the potential to be a first-in-class neuronal progenitor cell therapeutics that is likely to promote quicker recovery and improve neurological outcome in cerebral ischemic stroke patients.
Study: NCT02626442

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: 6 month group exercise class
Study: NCT03045913

Intervention type: DEVICE
Intervention: Genoss DES
Description: The Genoss DES (Genoss, Korea) L-605 cobalt chromium (CoCr) platform with a strut thickness of 70 µm Sirolimus drug with concentration of 1.15µg/mm2 Abluminal biodegradable PLA and PLGA polymers.
Study: NCT05980962

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Inferior oblique anteriorization
Description: symmterical anteriorization the the inferior oblique muscle 1 mm behind and lateral to the inferior rectus insertion
Study: NCT01368887

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotinamide Monotherapy
Description: The patient will apply the treatment twice daily in the morning and at bedtime on the involved area only. The scheduled treatment duration is 12 weeks. Patient to begin treatment on the night of Visit 1.
Study: NCT00430456

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Exercise
Description: Treadmill Training

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Treadmill Training
Study: NCT03682029

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin C (ascorbic acid)
Description: Monotherapy with oral vitamin C supplementation to elevate plasma vitamin C level to the upper end of the physiological range.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT00284154

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinflunine
Description: 320mg/m2 every 21 days as a 15-20 minute infusion
Study: NCT04624542

Intervention type: DEVICE
Intervention: Electromyographic device
Description: the EMG machine will be used to measure NCV of femoral nerve within individuals with PFPS

Intervention type: DEVICE
Intervention: Electromyographic device
Description: the EMG machine will be used to measure NCV of femoral nerve within individuals with PFPS
Study: NCT04516863

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: German Autobiographical Memory Interview short-form
Description: Diagnostic Test

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: German Autobiographical Memory Interview short-form
Description: Diagnostic Test
Study: NCT00591019

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Modafinil
Description: 200 mg/day, morning dose

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sugar pill once per day in the morning.
Study: NCT00657995

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Artificial Pancreas (STG-22)
Description: safe tool
Study: NCT05980962

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Inferior oblique anteriorization together with unliateral resction
Description: asymmterical surgery, anteriorization the the inferior oblique muscle 1 mm behind and lateral to the inferior rectus insertion in one eye, and an additional 3-5 mm resction of the inferior oblique in the eye with the larger devation
Study: NCT00845676

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated interferon alfa-2a + Ribavirin
Description: Pegylated interferon alfa-2a 180 mcg subcutaneous injection once weekly for 24 weeks Ribavirin 1000-1200mg daily, dosed according to body weight and divided twice daily, for 12-24 weeks
Study: NCT02535377

Intervention type: OTHER
Intervention: Sperm cryopreservation
Description: Sperm from the different groups are cryopreserved to evaluate their resistance to preservation.

Intervention type: OTHER
Intervention: Sperm cryopreservation
Description: Sperm from the different groups are cryopreserved to evaluate their resistance to preservation.
Study: NCT01033708

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: narrative exposure therapy
Description: Narrative Exposure Therapy (NET), an evidence-based trauma-focussed treatment, suitable for survivors of prolonged and repeated exposure to traumatic stress and childhood adversities

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: narrative exposure therapy
Description: Narrative Exposure Therapy (NET), an evidence-based trauma-focussed treatment, suitable for survivors of prolonged and repeated exposure to traumatic stress and childhood adversities
Study: NCT01904747

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib administered Fasted
Description: palbociclib given under fasting 10 hrs overnight; capsule form, 125 mg single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib administered Fed high calorie
Description: palbociclib given right after a high fat high calorie meal; capsule form, 125 mg single dose
Study: NCT02050698

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Protected weightbearing in a hard-soled shoe
Description: Patients allocated to experiment group are allowed tolerable weightbearing in a hard-soled shoe after one week of immobilization in a posterior splint
Study: NCT01904747

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib administered Fed low calorie
Description: palbociclib given right after a low fat low calorie meal; capsule form, 125 mg single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib administered Fed moderate calorie
Description: palbociclib given between moderate calorie meal; capsule form, 125 mg single dose
Study: NCT03996564

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Battlefield Acupuncture
Description: 1-10 needles inserted in systematic nature as described by Battlefield acupuncture protocol.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: Acetaminophen 500mg-1000mg,

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac
Description: Diclofenac 50mg-75 mg orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diazepam
Description: Diazepam 5mg-10 mg intravenous or oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocodone
Description: Hydrocodone 5mg/325mg-10mg/650mg mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac
Description: oral, or intramuscular Ketorolac 30mg-60 mg
Study: NCT02830932

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VXA-RSV-f Tablets (high dose)
Description: The drug product will be provided as small white enteric-coated tablets. Multiple tablets may be administered to delivered the high dose.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: VXA Placebo Tablets
Description: The placebo will be provided as small white enteric-coated tablets that are similar in size and number to the active drug product tablets.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VXA-RSV-f Tablets (low dose)
Description: The drug product will be provided as small white enteric-coated tablets. Multiple tablets may be administered to delivered the low dose
Study: NCT04456166

Intervention type: DIETARY_SUPPLEMENT
Intervention: noNPO
Description: Patients with diabetes mellitus type 2 who are planned to receive a carbohydrate beverage (400 ml (12.8% carbohydrates, 50 kcal/100 ml; Nucare NONPO Ⓡ , Daesang Wellife, Korea) before the operation and up to 2 hours before the induction of anesthesia outside this clinical study setting will be asked to be enrolled into the study.~Before induction of general anesthesia, all patients were evaluated the gastric volume under ultrasonography.
Study: NCT04374292

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family intervention
Description: Topics covered in each session with intervention group mothers.~1. Dietary and physical activity habits and their link to obesity and cardio-metabolic diseases. Children learn about healthy eating habits and health risks at home.~2. Food-preparation processes. Selecting and purchasing food and beverages; importance of food groups and their impact on health; importance of fruit and vegetables. Balance between food groups, source of foods, organic or industrialized. Family menu preparation.~3. Habits and behaviors surrounding eating processes identified as health or risk factors, such as energy density, portion-size control, controlling emotional eating.~4. Beverages. Water versus sugar-sweetened drinks prepared at home or purchased at the store.~5. Preventing the risk of cardiovascular diseases by learning healthy eating habits and practicing these habits at home.~6. Integration. Practicing the skills learned during the intervention in each stage of preparing food and eating

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual nutritional consultation
Description: Control group mothers and children (n = 87) were given the usual nutritional consultation and were prescribed diets that covered their energy requirements according to their age and sex. CG mother/child pairs received information regarding food groups and portion sizes, were trained in the use of the food equivalence system to encourage variation, and were instructed on how to prepare the diet at home.
Study: NCT02050698

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Protected weightbearing in a short leg walking cast
Description: Patients allocated to control group are allowed tolerable weightbearing in a short leg walking cast after one week of immobilization in a posterior splint
Study: NCT04482036

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mobile Phone Application Assessments
Description: The BrainCare Notes app was designed to be installed on the caregiver's phone. It has the capacity to send Neuropsychiatric Inventory Questionnaire (NPI-Q) assessments to the caregiver. If the answers to the behavioral and psychological symptoms rise above the threshold, the clinicians will be notified, and a care plan will be enacted, in order to keep the patient and caregiver safe.~The application also has the ability to send and receive private messages between caregiver and the patient's clinical care team.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard Assessments
Description: The caregiver and patient will receive the same questionnaires and surveys that the intervention group will receive. However, they will not receive the mobile phone application questionnaires.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Assessments
Description: The caregiver and patient will receive the same questionnaires and surveys that the intervention group will receive. However, they will not receive the mobile phone application questionnaires.
Study: NCT02578940

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-Fluciclovine PET CT
Description: Radioligand for PET CT scanning
Study: NCT01309451

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: intravitreal, 1.25mg., monthly

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: intravitreal, 1.25mg., monthly

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexamethasone intravitreal implant
Description: 0.7mg, intravitreal every 4 months
Study: NCT00482599

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex
Description: 2 mg/kg sugammadex administered intravenously at reappearance of T2 after 0.6 mg/kg rocuronium in patients with renal impairment and control patients

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sugammadex
Description: 2 mg/kg sugammadex administered intravenously at reappearance of T2 after 0.6 mg/kg rocuronium in patients with renal impairment and control patients